Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Drug Delivery

Exclusive interview

Aptar Pharma says new eDevices will speed up regulatory approval

By Natalie Morrison+

21-Feb-2012

Loading...

Aptar Pharma says its new eDevices can help companies gain quicker regulatory approval for their nasal drug products without having to re-do clinical trials.

The firm gave in-PharmaTechnologist an exclusive first look at its newly expanded measured dosage tech at last week’s Pharmapack Europe 2012.

Joachim Koerner, VP of eDevice R&D, prescription division, said the platform – which consists of dose display e-Dose Counter, and dose restrictor e-Lockout – is the type of controlled self-administration measure regulators are leaning towards at the moment.

He said: “More and more regulators are asking for safety features added to products, for instance to prevent overdosing, like our e-Lockout system does.

“For example in the US the regulators ask for dose counters or indicators when you try to get new asthma COPD (chronic obstructive pulmonary disease) inhalers or other pressurized metered-dose inhalers (pDMI) into the market.

“We meet the regulator recommendations for nasal spray devices and pDMIs and also pain treatment.”

He added that the platform technology offering is highly customisable, and will therefore save clients the time and expense of trial do-overs.

“We have a close link to the primary package,” he said. “We know exactly what the performance of the primary package is and do not touch the spray performance characteristics of the primary package while adapting our eDevice.

“That means there is no need to re-do clinical studies and so they save a lot of time and money.”

Related products

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

ASI has teamed up with Chromatan in order to deliver single-use and column-free capture...

Updated IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests

John Giannone - incoming IPEC-Americas chairman

Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

Special Report from ATMI's Belgian Facility

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

Walter Dissinger

President , BASF nutrition and health

Optimism is returning to the pharma fine chemicals sector, says analyst

Optimism is returning to the pharma fine chemicals sector, says analyst

Jan Ramakers

Industry consultant, Jan Ramakers Fine Chemical Consulting Group

Capsugel expands liquid fill capsule capabilities

Keith Hutchison,

Senior VP of research and development (R&D) , Capsugel

New filtration tech boosts biomanufacturing yields, says Sartorius

New filtration tech boosts biomanufacturing yields, says Sartorius

Jens Meyer

Product manager for filtration technologies, Sartorius Stedim

Submit good REMS proposals for FDA brownie points, says RAPS author

Submit good REMS proposals for FDA brownie points, says RAPS author

Ed Tabor

VP of strategic drug development , Quintiles

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Missy Lowery

Marketing Manager for the Americas, Capsugel

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Cory Stevenson & Brandon Pence

Thermo Fisher Scientific

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

Eric Isberg

Global Product Manager, ATMI

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Key Industry Events

 

Access all events listing

Our events, Events from partners...